BAJAJ BROKING
Lupin Limited announced its financial results for Q4 FY24-25, reporting a significant 112.5% year-on-year (YoY) rise in net profit to Rs.782 crore, up from Rs.368 crore in the same quarter last year. Revenue from operations grew 13.6% YoY to Rs.5,562 crore. The company maintained strong operational efficiency, reflected in a 34.3% YoY increase in EBITDA to Rs.1,378 crore and margin expansion of 381 basis points to 24.8%. The Board also recommended a dividend of 600%.
Revenue: Rs.5,562 crore, up 13.6% YoY
Net Profit: Rs.782 crore, up 112.5% YoY
EBITDA: Rs.1,378 crore, up 34.3% YoY
EBITDA Margin: 24.8%, up 381 bps YoY
PAT Margin: 14.1%, up 660 bps YoY
Dividend: 600% recommended for FY25
Share Price (NSE): Rs.1,530, up 1.6% post-results
Lupin’s robust Q4 performance was led by strong sales in the US and India. The US market contributed Rs.2,262 crore, rising 19% YoY, supported by new launches and volume traction. India sales grew 6.9% YoY to Rs.1,711 crore, with strength in chronic therapies. Other developed markets surged 30% YoY, while emerging markets saw a 10.4% YoY increase. API sales, however, declined 10.3% YoY due to price pressure.
North America: Q4 revenue rose 19% YoY to Rs.2,262 crore, driven by product launches and expansion of generic portfolio.
India: Sales grew 6.9% YoY to Rs.1,711 crore, aided by chronic segment growth and four new brand launches.
Other Developed Markets: Revenue increased 30% YoY to Rs.691 crore, with strong contributions from Germany and Australia.
Emerging Markets: Sales rose 10.4% YoY to Rs.666 crore, led by Mexico and Africa despite pressure in Philippines and Brazil.
API Business: Q4 revenue declined to Rs.232 crore, down 10.3% YoY due to normalised volumes and price adjustments.
Analysts anticipated growth in Lupin’s US generics and India formulations, along with improved margins. The company delivered on both counts, with EBITDA margin improving to 24.8% and PAT more than doubling. R&D spend for the quarter stood at Rs.534 crore, or 9.6% of sales, reaffirming focus on complex generics.
Lupin’s leadership credited the strong FY25 close to improved commercial execution, enhanced operational efficiencies, and product launches across major markets. They remain optimistic about sustaining momentum into FY26 through focused R&D and margin resilience.
Metric | Q4 FY24-25 | Q4 FY23-24 | YoY Change (%) |
Revenue from Operations | Rs.5,562 crore | Rs.4,895 crore | +13.6% |
EBITDA | Rs.1,378 crore | Rs.1,026 crore | +34.3% |
EBITDA Margin (%) | 24.8% | 21.0% | +381 bps |
Net Profit (PAT) | Rs.782 crore | Rs.368 crore | +112.5% |
PAT Margin (%) | 14.1% | 7.5% | +660 bps |
R&D Spend | Rs.534 crore | Rs.426 crore | +25.3% |
Dividend (FY25) | 600% | – | – |
Share Price (NSE) | Rs.1,530 | – | +1.6% (Intraday) |
For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.
Source: Lupin – Board Meeting Outcome and Audited Q4 FY25 Financial Results (14 May 2025).
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading